ACAD Logo

ACADIA Pharmaceuticals Inc. (ACAD) 

NASDAQ
Market Cap
$2.72B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
515 of 971
Rank in Industry
280 of 557

Largest Insider Buys in Sector

ACAD Stock Price History Chart

ACAD Stock Performance

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Activity of ACADIA Pharmaceuticals Inc.

Over the last 12 months, insiders at ACADIA Pharmaceuticals Inc. have bought $0 and sold $3.04M worth of ACADIA Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at ACADIA Pharmaceuticals Inc. have bought $31.9M and sold $12.58M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 294,154 shares for transaction amount of $7.45M was made by BAKER BROS. ADVISORS LP () on 2023‑05‑24.

List of Insider Buy and Sell Transactions, ACADIA Pharmaceuticals Inc.

2024-11-19SaleEVP, COO, HEAD OF COMMERCIAL
10,329
0.0065%
$16.81$173,630-3.45%
2024-11-19SaleEVP, CHIEF FINANCIAL OFFICER
10,259
0.0064%
$16.81$172,454-3.45%
2024-11-19SalePRINCIPAL ACCOUNTING OFFICER
4,073
0.0025%
$16.81$68,467-3.45%
2024-08-19SaleCEO
31,747
0.0186%
$15.28$485,094+1.08%
2024-08-19SaleEVP, COO, HEAD OF COMMERCIAL
9,534
0.0056%
$15.28$145,680+1.08%
2024-08-19SaleEVP, CHIEF FINANCIAL OFFICER
9,733
0.0057%
$15.28$148,720+1.08%
2024-06-10SaleEVP, CHIEF FINANCIAL OFFICER
975
0.0006%
$14.79$14,420+6.12%
2024-05-02SaleCEO
11,427
0.0069%
$16.94$193,573-8.44%
2024-05-02SaleEVP, COO, HEAD OF COMMERCIAL
3,477
0.0021%
$16.94$58,900-8.44%
2024-05-02SaleEVP, CHIEF FINANCIAL OFFICER
3,503
0.0021%
$16.94$59,341-8.44%
2024-05-02SalePRINCIPAL ACCOUNTING OFFICER
1,326
0.0008%
$16.94$22,462-8.44%
2024-04-08SaleCEO
26,574
0.0162%
$17.87$474,877-11.12%
2024-04-08SaleEVP, COO, HEAD OF COMMERCIAL
2,568
0.0016%
$17.87$45,890-11.12%
2024-04-08SaleEVP, CHIEF FINANCIAL OFFICER
2,716
0.0017%
$17.87$48,535-11.12%
2024-04-08SalePRINCIPAL ACCOUNTING OFFICER
1,790
0.0011%
$17.87$31,987-11.12%
2024-03-27SaleCEO
17,714
0.0106%
$17.90$317,081-12.39%
2024-03-27SaleEVP, COO, HEAD OF COMMERCIAL
5,140
0.0031%
$17.90$92,006-12.39%
2024-03-27SaleEVP, CHIEF FINANCIAL OFFICER
5,434
0.0032%
$17.90$97,269-12.39%
2024-02-26SaleCEO
5,577
0.0032%
$24.67$137,585-37.07%
2024-02-26SaleEVP, COO, HEAD OF COMMERCIAL
624
0.0004%
$24.67$15,394-37.07%

Insider Historical Profitability

19.44%
DAVIS STEPHENCEO
186555
0.1121%
$16.32030
Teehan BrendanEVP, COO, HEAD OF COMMERCIAL
62105
0.0373%
$16.32016
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
53302
0.032%
$16.32015
KIM AUSTIN D.EVP,General Counsel, Secretary
46901
0.0282%
$16.32015
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
19863
0.0119%
$16.32014
BAKER BROS. ADVISORS LP
39058564
23.4738%
$16.32160+14.48%
14159, L.P.
20278008
12.1869%
$16.3210+3.15%
BAKER FELIX
18001203
10.8186%
$16.3240+58.48%
OXFORD BIOSCIENCE PARTNERS IV LP10 percent owner
3160238
1.8993%
$16.3220+29.7%
WALTON ALAN G
2573836
1.5469%
$16.3210+11.11%
van Osch Martiendirector
1168892
0.7025%
$16.3220+29.7%
GORDON CARL Ldirector
774006
0.4652%
$16.3220+29.7%
Brann Mark RPresident & CSO
317756
0.191%
$16.3209
Hacksell UliCEO
115549
0.0694%
$16.32122+11.11%
Baity GlennEVP AND GC
83734
0.0503%
$16.32025
Stankovic Srdjan R.President
61234
0.0368%
$16.32023
Iversen Leslie Ldirector
36127
0.0217%
$16.3214
Mills RogerEVP, DEVELOPMENT AND CMO
18550
0.0111%
$16.3203
Brege Lauradirector
13502
0.0081%
$16.32012
Ridloff ElenaEVP and CFO
10553
0.0063%
$16.3206
SOLAND DANIEL Bdirector
10000
0.006%
$16.3220<0.0001%
KAPLAN LESTER J PH Ddirector
8500
0.0051%
$16.3203
Rasmussen Torstendirector
8500
0.0051%
$16.3206
YANG MICHAEL J.EVP and CCO
8059
0.0048%
$16.3207
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
1671
0.001%
$16.3204
HARRIGAN EDMUNDdirector
1000
0.0006%
$16.3210<0.0001%
Miller Eric AlejandroController & PAO
270
0.0002%
$16.3203
BORER MICHAEL Tdirector
0
0%
$16.3202
GRAY MARY ANNdirector
0
0%
$16.3203
Aasen Thomas HEXEC VP, CFO AND CBO
0
0%
$16.32015
Lundstrom BrianSr. VP, Bus. Devt.
0
0%
$16.3205
Wells William McDowalldirector
0
0%
$16.3204
Daly James Mdirector
0
0%
$16.3202

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$792.57M25.9442.86M0%+$05.69
RTW Investments, LP$255.7M8.3713.83M+22.89%+$47.63M3.83
The Vanguard Group$245.89M8.0513.3M-0.73%-$1.8M0.01
BlackRock$215.76M7.0611.67M+2.26%+$4.78M0.01
State Street$110.97M3.636M-7.17%-$8.57M0.01
Ecor1 Capital Llc$110.78M3.635.99M0%+$00.78
T. Rowe Price$73.95M2.424M-22.77%-$21.8M0.01
Fidelity Investments$73.85M2.423.99M-24.15%-$23.51M0.01
Geode Capital Management$51.65M1.692.79M+3.75%+$1.87M<0.01
D. E. Shaw & Co.$48.85M1.62.64M-29.63%-$20.57M0.05
Palo Alto Investors Lp$44.65M1.462.41M+0.22%+$99,605.635.04
Alger$41.74M1.372.26M-28.93%-$17M0.21
Millennium Management LLC$38.93M1.272.11M+19.3%+$6.3M0.03
Emerald Advisers, Inc.$30.53M11.65M+0.34%+$102,785.911.24
First Trust$30.49M11.65M-7.23%-$2.38M0.03
Jupiter Fund Management$29.65M0.971.6M+21.28%+$5.2M0.08
Morgan Stanley$27.05M0.891.46M+7.42%+$1.87M<0.01
Voloridge Investment Management, LLC$25.11M0.821.36M+5.91%+$1.4M0.09
EMERALD MUTUAL FUND ADVISERS TRUST$23.12M0.761.25M-4.16%-$1M1.21
Northern Trust$22.04M0.721.19M-1.84%-$412,456.43<0.01
Charles Schwab$21.99M0.721.19M+5.42%+$1.13M0.01
The Manufacturers Life Insurance Company$21.66M0.711.17M+38.48%+$6.02M0.02
Prudential Financial$19.83M0.651.07M+142.09%+$11.64M0.03
Deutsche Bank$19.01M0.621.03M+0.27%+$51,882.940.01
Squarepoint Ops LLC$18.66M0.611.01M+264.19%+$13.53M0.07
Connor Clark & Lunn Investment Management Ltd$15.83M0.52856,299+36.49%+$4.23M0.04
FINEPOINT CAPITAL LP$15.54M0.51840,453+9.2%+$1.31M2.5
Rockefeller Capital Management L P$14.58M0.48788,452+41.72%+$4.29M0.04
Point72 Asset Management$14.36M0.47776,700+97.72%+$7.1M0.02
Ameriprise Financial$13.72M0.45742,183+14.69%+$1.76M<0.01
Goldman Sachs$13.46M0.44727,905-9.48%-$1.41M<0.01
Panagora$12.97M0.42701,292+8.74%+$1.04M0.07
Capital Fund Management$12.86M0.42695,547+185.28%+$8.35M0.11
Rice Hall James & Associates, LLC$12.29M0.4664,556-4.08%-$523,193.020.73
Canada Pension Plan Investment Board$12.23M0.4661,600New+$12.23M0.01
Qube Research & Technologies$11.91M0.39644,070+129.81%+$6.73M0.01
Avidity Partners Management Lp$10.88M0.36588,500New+$10.88M0.41
Renaissance Technologies$10.61M0.35573,800+211.85%+$7.21M0.02
Citadel Advisors LLC$10.53M0.35569,258+271.98%+$7.7M0.01
Marshall Wace$9.66M0.32522,413New+$9.66M0.01
Tang Capital Management, LLC$9.59M0.31518,900+353.58%+$7.48M0.04
BNY Mellon$9.3M0.3503,053-8.69%-$884,912.82<0.01
JPMorgan Chase$8.78M0.29475,004-28.13%-$3.44M<0.01
Frazier Life Sciences Management L P$8.7M0.29470,338-35.65%-$4.82M0.39
Macquarie Group$8.64M0.28467,455+433.33%+$7.02M0.01
Cubist Systematic Strategies$8.35M0.27451,518+17.2%+$1.23M0.07
Nuveen$8.1M0.27437,878+4.99%+$384,702.93<0.01
Candriam S C A$7.5M0.25405,751New+$7.5M0.05
Rafferty Asset Management Llc$7.23M0.24391,225-8.58%-$678,675.430.02
Jane Street Capital$6.95M0.23376,061-15.74%-$1.3M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.